Skip to content

Preoperative Decolonization and Surgical Site Infections - a Prospective Randomized Trial

Preoperative Decolonization and Surgical Site Infections - a Prospective Randomized Trial (DECO-SSI Trial)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02560155
Acronym
DECO-SSI
Enrollment
1300
Registered
2015-09-25
Start date
2015-11-30
Completion date
2018-02-28
Last updated
2018-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Orthopedic Disorders, Surgical Site Infection

Keywords

Orthopedic surgery, Surgical site infection, Decolonization, Staphylococcus aureus

Brief summary

Surgical site infections are a major postoperative complication and are mostly due to colonization with endogenous germs, like Staphylococcus aureus, Staphylococcus epidermidis or Propionibacterium acnes. In literature, preoperative decolonization procedures showed a trend in lowering surgical site infection rates, but especially in orthopedic surgery data is controversial and randomized controlled trials are lacking. In the main study, the study investigators aim at performing a controlled prospective randomized interventional trial to measure the impact of preoperative decolonization of nasal Staphylococcus aureus carriers on surgical site infection rates in orthopedic surgery. In an alongside study a controlled prospective randomized interventional trial to measure the impact of preoperative skin decolonization of patients undergoing an orthopedic procedure will be conducted.

Detailed description

All participants will be assessed for eligibility during preoperative othopedic consultation. 2-3 weeks prior operation date participants will be screened for Staph. aureus carriage by nose-swab. According to nose-swab results randomizaton and allocation to study arm will be performed. After one and three months post-operatively participants will be asked by phone interview if surgical site infections occured. Results have to be confirmed by orthopedic surgeon if possible.

Interventions

DRUGMupirocin 2% nasal ointement

Mupirocin nasal ointement 2x/d for 5 days preoperatively

DRUGChlorhexidine sol 4%

Shower with Chlorhexidine sol 4% once a day for 5 days preoperatively

Sponsors

Clinical Trials Unit Bern (CTU)
CollaboratorUNKNOWN
Lindenhofstiftung
CollaboratorUNKNOWN
Labormedizinisches Zentrum Dr. Risch
CollaboratorINDUSTRY
Lindenhofgruppe AG
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patient older than 16 years * patient undergoing elective orthopedic procedure at the Sonnenhof hospital * decolozination protocol can be performed timely * signed informed consent

Exclusion criteria

* no orthopedic surgery planned * allergy to mupirocin or chlorhexidine * presence of a nasal foreign body * no informed consent * pregnancy * decolozination protocol can't be followed timely * patients undergoing treatment/surgery for a documented infection

Design outcomes

Primary

MeasureTime frameDescription
Overall number of participants with surgical site infections 3 months postoperatively3 monthsPhone interview and orthopedic assessement

Secondary

MeasureTime frameDescription
Number of participants with surgical site infections at 1 and 3 months postoperatively1 and 3 monthsPhone interview and orthopedic assessement

Other

MeasureTime frameDescription
Total screening costsone yearTotal screening costs divided by the number of prevented SSI to assess cost-effectiveness

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026